JPH0337539B2 - - Google Patents
Info
- Publication number
- JPH0337539B2 JPH0337539B2 JP12820783A JP12820783A JPH0337539B2 JP H0337539 B2 JPH0337539 B2 JP H0337539B2 JP 12820783 A JP12820783 A JP 12820783A JP 12820783 A JP12820783 A JP 12820783A JP H0337539 B2 JPH0337539 B2 JP H0337539B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- carbon atoms
- group
- general formula
- methoxybenzaldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 phosphorus compound Chemical class 0.000 claims description 29
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 239000011574 phosphorus Substances 0.000 claims description 19
- 229910052698 phosphorus Inorganic materials 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 239000002904 solvent Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000001816 cooling Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 150000003935 benzaldehydes Chemical class 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- NZHGWWWHIYHZNX-UHFFFAOYSA-N 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C=CC(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-UHFFFAOYSA-N 0.000 description 4
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 238000007239 Wittig reaction Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 3
- 229940102398 methyl anthranilate Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 3
- WYHMNJKAVNPOOR-UHFFFAOYSA-N (2-acetyloxy-4-formylphenyl) acetate Chemical compound CC(=O)OC1=CC=C(C=O)C=C1OC(C)=O WYHMNJKAVNPOOR-UHFFFAOYSA-N 0.000 description 2
- WZUODJNEIXSNEU-UHFFFAOYSA-N 2-Hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(O)=C1 WZUODJNEIXSNEU-UHFFFAOYSA-N 0.000 description 2
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- FZHSPPYCNDYIKD-UHFFFAOYSA-N 5-methoxysalicylaldehyde Chemical compound COC1=CC=C(O)C(C=O)=C1 FZHSPPYCNDYIKD-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000012433 hydrogen halide Substances 0.000 description 2
- 229910000039 hydrogen halide Inorganic materials 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 2
- JFZUABNDWZQLIJ-UHFFFAOYSA-N methyl 2-[(2-chloroacetyl)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)CCl JFZUABNDWZQLIJ-UHFFFAOYSA-N 0.000 description 2
- MSSVHVCWXITNDU-UHFFFAOYSA-N methyl 2-[3-(3,4-dimethoxyphenyl)prop-2-enoylamino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C=CC1=CC=C(OC)C(OC)=C1 MSSVHVCWXITNDU-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- JJVNINGBHGBWJH-UHFFFAOYSA-N ortho-vanillin Chemical compound COC1=CC=CC(C=O)=C1O JJVNINGBHGBWJH-UHFFFAOYSA-N 0.000 description 2
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical class PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- PZSJOBKRSVRODF-UHFFFAOYSA-N vanillin acetate Chemical compound COC1=CC(C=O)=CC=C1OC(C)=O PZSJOBKRSVRODF-UHFFFAOYSA-N 0.000 description 2
- AJNKRQSECUQOPV-UHFFFAOYSA-N (2-formyl-4-methoxyphenyl) acetate Chemical compound COC1=CC=C(OC(C)=O)C(C=O)=C1 AJNKRQSECUQOPV-UHFFFAOYSA-N 0.000 description 1
- AZBWXJIEXMGFGN-UHFFFAOYSA-N (2-formyl-5-methoxyphenyl) acetate Chemical compound COC1=CC=C(C=O)C(OC(C)=O)=C1 AZBWXJIEXMGFGN-UHFFFAOYSA-N 0.000 description 1
- XRERBLZFZMBKRU-UHFFFAOYSA-N (2-formyl-6-methoxyphenyl) acetate Chemical compound COC1=CC=CC(C=O)=C1OC(C)=O XRERBLZFZMBKRU-UHFFFAOYSA-N 0.000 description 1
- ZVPGTXJXZIXWGR-UHFFFAOYSA-N (5-formyl-2-methoxyphenyl) acetate Chemical compound COC1=CC=C(C=O)C=C1OC(C)=O ZVPGTXJXZIXWGR-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IAJBQAYHSQIQRE-UHFFFAOYSA-N 2,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(OC)=C(C=O)C=C1OC IAJBQAYHSQIQRE-UHFFFAOYSA-N 0.000 description 1
- FSKJPXSYWQUVGO-UHFFFAOYSA-N 2-[3-(4-hydroxy-3-methoxyphenyl)prop-2-enoylamino]benzoic acid Chemical compound C1=C(O)C(OC)=CC(C=CC(=O)NC=2C(=CC=CC=2)C(O)=O)=C1 FSKJPXSYWQUVGO-UHFFFAOYSA-N 0.000 description 1
- FHALBHJLYWQNFN-UHFFFAOYSA-N 2-butan-2-yloxy-3-methoxybenzaldehyde Chemical compound CCC(C)OC1=C(OC)C=CC=C1C=O FHALBHJLYWQNFN-UHFFFAOYSA-N 0.000 description 1
- KFSWONZYRSVJJQ-UHFFFAOYSA-N 2-butoxy-3-methoxybenzaldehyde Chemical compound CCCCOC1=C(OC)C=CC=C1C=O KFSWONZYRSVJJQ-UHFFFAOYSA-N 0.000 description 1
- VFKFKKNOQRIWLE-UHFFFAOYSA-N 2-butoxy-4-methoxybenzaldehyde Chemical compound CCCCOC1=CC(OC)=CC=C1C=O VFKFKKNOQRIWLE-UHFFFAOYSA-N 0.000 description 1
- FFOPXTXCKNPWPB-UHFFFAOYSA-N 2-butoxy-5-methoxybenzaldehyde Chemical compound CCCCOC1=CC=C(OC)C=C1C=O FFOPXTXCKNPWPB-UHFFFAOYSA-N 0.000 description 1
- DMPUNCUVRGJYGL-UHFFFAOYSA-N 2-ethoxy-3-methoxybenzaldehyde Chemical compound CCOC1=C(OC)C=CC=C1C=O DMPUNCUVRGJYGL-UHFFFAOYSA-N 0.000 description 1
- QXAVANUCHWRYFF-UHFFFAOYSA-N 2-ethoxy-4-methoxybenzaldehyde Chemical compound CCOC1=CC(OC)=CC=C1C=O QXAVANUCHWRYFF-UHFFFAOYSA-N 0.000 description 1
- VWELEPLJZIXGFW-UHFFFAOYSA-N 2-ethoxy-5-methoxybenzaldehyde Chemical compound CCOC1=CC=C(OC)C=C1C=O VWELEPLJZIXGFW-UHFFFAOYSA-N 0.000 description 1
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 description 1
- CFAOCSWXHILAAK-UHFFFAOYSA-N 3,4-dibutoxybenzaldehyde Chemical compound CCCCOC1=CC=C(C=O)C=C1OCCCC CFAOCSWXHILAAK-UHFFFAOYSA-N 0.000 description 1
- IOKYUTCABAXWAK-UHFFFAOYSA-N 3,4-dipropoxybenzaldehyde Chemical compound CCCOC1=CC=C(C=O)C=C1OCCC IOKYUTCABAXWAK-UHFFFAOYSA-N 0.000 description 1
- QUTAHKMUOGGGGW-UHFFFAOYSA-N 3-butan-2-yloxy-4-methoxybenzaldehyde Chemical compound CCC(C)OC1=CC(C=O)=CC=C1OC QUTAHKMUOGGGGW-UHFFFAOYSA-N 0.000 description 1
- CSSRHTDXZIBTMI-UHFFFAOYSA-N 3-butoxy-4-methoxybenzaldehyde Chemical compound CCCCOC1=CC(C=O)=CC=C1OC CSSRHTDXZIBTMI-UHFFFAOYSA-N 0.000 description 1
- VAMZHXWLGRQSJS-UHFFFAOYSA-N 3-ethoxy-4-methoxybenzaldehyde Chemical compound CCOC1=CC(C=O)=CC=C1OC VAMZHXWLGRQSJS-UHFFFAOYSA-N 0.000 description 1
- JRUKQVINIBATNZ-UHFFFAOYSA-N 3-methoxy-2-propan-2-yloxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1OC(C)C JRUKQVINIBATNZ-UHFFFAOYSA-N 0.000 description 1
- FULGZQOQNLDCDB-UHFFFAOYSA-N 3-methoxy-2-propoxybenzaldehyde Chemical compound CCCOC1=C(OC)C=CC=C1C=O FULGZQOQNLDCDB-UHFFFAOYSA-N 0.000 description 1
- BSVXIKDDVDCMIO-UHFFFAOYSA-N 3-methoxy-4-propan-2-yloxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1OC(C)C BSVXIKDDVDCMIO-UHFFFAOYSA-N 0.000 description 1
- YUWQIFGCZPFOAL-UHFFFAOYSA-N 3-methoxy-4-propoxybenzaldehyde Chemical compound CCCOC1=CC=C(C=O)C=C1OC YUWQIFGCZPFOAL-UHFFFAOYSA-N 0.000 description 1
- BERFDQAMXIBOHM-UHFFFAOYSA-N 4-Ethoxy-3-methoxybenzaldehyde Chemical compound CCOC1=CC=C(C=O)C=C1OC BERFDQAMXIBOHM-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- HLWKDCMKTGMQNT-UHFFFAOYSA-N 4-butan-2-yloxy-3-methoxybenzaldehyde Chemical compound CCC(C)OC1=CC=C(C=O)C=C1OC HLWKDCMKTGMQNT-UHFFFAOYSA-N 0.000 description 1
- VDQRSBASPLRAOM-UHFFFAOYSA-N 4-butoxy-3-methoxybenzaldehyde Chemical compound CCCCOC1=CC=C(C=O)C=C1OC VDQRSBASPLRAOM-UHFFFAOYSA-N 0.000 description 1
- BYJIIHCWYHPWQD-UHFFFAOYSA-N 4-methoxy-2-propan-2-yloxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(OC(C)C)=C1 BYJIIHCWYHPWQD-UHFFFAOYSA-N 0.000 description 1
- VFKVHYJCOWKQQY-UHFFFAOYSA-N 4-methoxy-2-propoxybenzaldehyde Chemical compound CCCOC1=CC(OC)=CC=C1C=O VFKVHYJCOWKQQY-UHFFFAOYSA-N 0.000 description 1
- XLUAYJHDQOQHPB-UHFFFAOYSA-N 4-methoxy-3-propan-2-yloxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OC(C)C XLUAYJHDQOQHPB-UHFFFAOYSA-N 0.000 description 1
- OQGTYVGUCWWYNK-UHFFFAOYSA-N 4-methoxy-3-propoxybenzaldehyde Chemical compound CCCOC1=CC(C=O)=CC=C1OC OQGTYVGUCWWYNK-UHFFFAOYSA-N 0.000 description 1
- RHPBEIFTLFTUQZ-UHFFFAOYSA-N 5-methoxy-2-propan-2-yloxybenzaldehyde Chemical compound COC1=CC=C(OC(C)C)C(C=O)=C1 RHPBEIFTLFTUQZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- WPUJEWVVTKLMQI-UHFFFAOYSA-N benzene;ethoxyethane Chemical compound CCOCC.C1=CC=CC=C1 WPUJEWVVTKLMQI-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- PYFRLDVYGBCYLI-UHFFFAOYSA-N decyl dihydrogen phosphite Chemical compound CCCCCCCCCCOP(O)O PYFRLDVYGBCYLI-UHFFFAOYSA-N 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- BJLZAAWLLPMZQR-UHFFFAOYSA-N oxo-di(propan-2-yloxy)phosphanium Chemical compound CC(C)O[P+](=O)OC(C)C BJLZAAWLLPMZQR-UHFFFAOYSA-N 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 description 1
- XTTGYFREQJCEML-UHFFFAOYSA-N tributyl phosphite Chemical compound CCCCOP(OCCCC)OCCCC XTTGYFREQJCEML-UHFFFAOYSA-N 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- RMZAYIKUYWXQPB-UHFFFAOYSA-N trioctylphosphane Chemical compound CCCCCCCCP(CCCCCCCC)CCCCCCCC RMZAYIKUYWXQPB-UHFFFAOYSA-N 0.000 description 1
- SJHCUXCOGGKFAI-UHFFFAOYSA-N tripropan-2-yl phosphite Chemical compound CC(C)OP(OC(C)C)OC(C)C SJHCUXCOGGKFAI-UHFFFAOYSA-N 0.000 description 1
- UYUUAUOYLFIRJG-UHFFFAOYSA-N tris(4-methoxyphenyl)phosphane Chemical compound C1=CC(OC)=CC=C1P(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 UYUUAUOYLFIRJG-UHFFFAOYSA-N 0.000 description 1
- WXAZIUYTQHYBFW-UHFFFAOYSA-N tris(4-methylphenyl)phosphane Chemical compound C1=CC(C)=CC=C1P(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 WXAZIUYTQHYBFW-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明は芳香族カルボン酸アミド誘導体の製造
方法に関するものである。
更に詳しくいえば、本発明はアレルギーに起因
する疾患の治療薬として有用な、一般式
(式中のR1は水素原子又は炭素数が1〜3の
低級アルキル基であり、R3は水素原子又は炭素
数が1〜3の低級アルキル基であり、Yは互いに
同じでも異なつていてもよく、それぞれ炭素数が
1〜4の直鎖状又は枝分れ状の低級アルコキシル
基、水酸基及び炭素数が2〜5の低級アシルオキ
シ基の中から選ばれる基であり、nは2又は3で
ある)
で表わされる芳香族カルボン酸アミド誘導体の製
造方法に関するものである。
本発明の製造方法によつて得られる一般式(1)で
表わされる化合物、特に式
で表わされる、N−(3,4−ジメトキシシンナ
モイル)アントラニル酸及びその薬理学的に許容
される塩は、人を含む哺乳動物において顕著な抗
アレルギー作用を示し、アレルギーに起因する
種々の疾患、例えば気管支ぜん息、アトピー性皮
フ炎、アレルギー性鼻炎などの予防及び治療用医
薬品としてきわめて有用である。
本発明は、このように医薬品として有用な一般
式(1)の化合物を効率よく製造する方法に関するも
のである。
本発明の方法によつて得られる一般式(1)の化合
物は公知の化合物であり、その製造方法も既にい
くつか提案されている。従来、この化合物は、一
般式
(式中のR1,Y及びnは前記と同じ意味をも
つ)
で表わされる核置換ケイ皮酸類の反応性官能的誘
導体と、一般式
(式中のR3は前記と同じ意味をもつ)
で表わされるアミノ安息香酸及びそのエステル類
とを反応させる方法(特公昭56−40710号、同56
−40711号、同57−47906号、同57−36905号)に
よつて専ら製造されていた。しかしながら、この
製造方法は操作が面倒な上、反応が加熱条件下で
行われるため出発原料の分解、副反応などによる
副生物が生じやすく、精製にも手間を要するもと
いう欠点があつた。その上、出発原料の核置換ケ
イ皮酸類(2)の反応性官能的誘導体として、例えば
酸ハロゲン化物を製造する時に、ハロゲン化水素
等の有害ガスが発生する等いくつかの難点があつ
た。
本発明者らはこれらの問題点を解決すべく研究
した結果、ウイテイヒ(Wittig)反応を応用する
ことにより、きわめて緩和な反応で、簡単かつ安
全に、効率よく目的物が製造できることを見出し
本発明をなすに至つた。すなわち本発明によれ
ば、一般式
〔式中のR1は前記と同じ意味をもち、R2は炭
素数が1〜3の低級アルキル基であり、Zは式、
The present invention relates to a method for producing aromatic carboxylic acid amide derivatives. More specifically, the present invention provides compounds of the general formula (R 1 in the formula is a hydrogen atom or a lower alkyl group having 1 to 3 carbon atoms, R 3 is a hydrogen atom or a lower alkyl group having 1 to 3 carbon atoms, and Y can be the same or different. and each is a group selected from a linear or branched lower alkoxyl group having 1 to 4 carbon atoms, a hydroxyl group, and a lower acyloxy group having 2 to 5 carbon atoms, and n is 2 or The present invention relates to a method for producing an aromatic carboxylic acid amide derivative represented by (3). Compounds represented by general formula (1) obtained by the production method of the present invention, especially formula N-(3,4-dimethoxycinnamoyl)anthranilic acid and its pharmacologically acceptable salts, represented by For example, it is extremely useful as a pharmaceutical for the prevention and treatment of bronchial asthma, atopic dermatitis, allergic rhinitis, and the like. The present invention thus relates to a method for efficiently producing the compound of general formula (1) useful as a pharmaceutical. The compound of general formula (1) obtained by the method of the present invention is a known compound, and several methods for its production have already been proposed. Traditionally, this compound has the general formula (R 1 , Y and n in the formula have the same meanings as above) and a reactive functional derivative of a nuclear-substituted cinnamic acid represented by the general formula (R 3 in the formula has the same meaning as above) A method of reacting aminobenzoic acid and its esters represented by
-40711, No. 57-47906, No. 57-36905). However, this production method has disadvantages in that it is cumbersome to operate, the reaction is carried out under heating conditions, which tends to produce by-products due to decomposition of starting materials, side reactions, etc., and also requires time and effort for purification. In addition, there were several drawbacks, such as the generation of harmful gases such as hydrogen halide when producing acid halides, for example, as reactive functional derivatives of the starting material nuclear-substituted cinnamic acids (2). As a result of research aimed at solving these problems, the present inventors discovered that by applying the Wittig reaction, the desired product could be produced simply, safely, and efficiently with an extremely mild reaction.The present invention is based on the present invention. I was able to accomplish this. That is, according to the present invention, the general formula [In the formula, R 1 has the same meaning as above, R 2 is a lower alkyl group having 1 to 3 carbon atoms, and Z is the formula,
【式】又は[Formula] or
【式】
(ただし、各式中のX1は炭素数が1〜10のア
ルキル基、フエニル基又は置換フエニル基、X2
は炭素数が1〜10のアルコキシル基、Halは塩素
原子、臭素原子又はヨウ素原子)で示される基で
ある〕
で表わされるリン化合物を塩基性物質で処理し
て、一般式
〔式中のR1及びR2は前記と同じ意味をもち、
Z′は式
(X1)3P−又は[Formula] (However, in each formula, X 1 is an alkyl group having 1 to 10 carbon atoms, a phenyl group, or a substituted phenyl group, X 2
is an alkoxyl group having 1 to 10 carbon atoms, and Hal is a group represented by a chlorine atom, bromine atom, or iodine atom.] A phosphorus compound represented by the following is treated with a basic substance to form the general formula [R 1 and R 2 in the formula have the same meanings as above,
Z′ is the formula (X 1 ) 3 P− or
【式】
(ただし、各式中のX1及びX2は前記と同じ意
味をもち、B+は塩基性物質から誘導される陽イ
オンである)で示される基である〕で表わされる
リンイリド誘導体を製造し、これと一般式、
(式中のY及びnは前記と同じ意味をもつ)
で表わされる核置換ベンズアルデヒド類とを反応
させることによつて、一般式、
(式中のR1,R2,Y及びnは前記と同じ意味
をもつ)
で表わされる芳香族カルボン酸アミド誘導体を製
造する。次いでこれを常法によりエステル基を加
水分解し、さらに所望に応じ生成物を塩に変える
ことによつて、一般式
(式中のR1およびnは前記と同じ意味をもち、
Y′は互いに同じでも異なつていてもよく、それ
ぞれ炭素数が1〜4の直鎖状又は枝分れ状の低級
アルコキシル基又は水酸基である)
で表わされる芳香族カルボン酸アミド誘導体及び
その薬理学的に許容される塩を製造することがで
きる。
本発明の製造方法は反応操作がきわめて簡単で
あり、反応も室温ないしは冷却下という緩和な条
件下で進行するため副生成物が少なく精製も容易
である。更に、例えば酸ハロゲン化物の製造時に
発生するハロゲン化水素ガスのような有害なガス
の発生も皆無である。このように、本製造方法は
従来の製造方法に比べ、きわめて容易に、効率よ
く目的物を製造することができる。
本発明の製造方法において原料として用いられ
る一般式(6)の核置換ベンズアルデヒド類は公知の
化合物であり、市販品として入手しうるか、ある
いは文献記載の方法により容易に製造しうるもの
である。このような化合物の例としては、
2,3−,2,4−,2,5−又は3,4−ジ
ヒドロキシベンズアルデヒド、2,3−,2,4
−,2,5−又は3,4−ジアセトキシベンズア
ルデヒド、2,3−,2,4−,2,5−,3,
4−又は3,5−ジメトキシベンズアルデヒド、
2,3−,2,4−,2,5−又は3,4−ジエ
トキシベンズアルヂヒド、2,3−,2,4−,
2,5−又は3,4−ジプロポキシベンズアルデ
ヒド、2,3−,2,4−,2,5−又は3,4
−ジブトキシベンズアルデヒド、2−ヒドロキシ
−3−メトキシベンズアルデヒド、2−ヒドロキ
シ−4−メトキシベンズアルデヒド、2−ヒドロ
キシ−5−メトキシベンズアルデヒド、3−ヒド
ロキシ−4−メトキシベンズアルデヒド、4−ヒ
ドロキシ−3−メトキシベンズアルデヒド、2−
アセトキシ−3−メトキシベンズアルデヒド、2
−アセトキシ−4−メトキシベンズアルデヒド、
2−アセトキシ−5−メトキシベンズアルデヒ
ド、3−アセトキシ−4−メトキシベンズアルデ
ヒド、4−アセトキシ−3−メトキシベンズアル
デヒド、2−エトキシ−3−メトキシベンズアル
デヒド、2−エトキシ−4−メトキシベンズアル
デヒド、2−エトキシ−5−メトキシベンズアル
デヒド、3−エトキシ−4−メトキシベンズアル
デヒド、4−エトキシ−3−メトキシベンズアル
デヒド、2−プロポキシ−3−メトキシベンズア
ルデヒド、2−プロポキシ−4−メトキシベンズ
アルデヒド、2−プロポキシ−5−メトキシベン
ズアルデヒド、3−プロポキシ−4−メトキシベ
ンズアルデヒド、4−プロポキシ−3−メトキシ
ベンズアルデヒド、2−ブトキシ−3−メトキシ
ベンズアルデヒド、2−ブトキシ−4−メトキシ
ベンズアルデヒド、2−ブトキシ−5−メトキシ
ベンズアルデヒド、3−ブトキシ−4−メトキシ
ベンズアルデヒド、4−ブトキシ−3−メトキシ
ベンズアルデヒド、2−イソプロポキシ−3−メ
トキシベンズアルデヒド、2−イソプロポキシ−
4−メトキシベンズアルデヒド、2−イソプロポ
キシ−5−メトキシベンズアルデヒド、3−イソ
プロポキシ−4−メトキシベンズアルデヒド、4
−イソプロポキシ−3−メトキシベンズアルデヒ
ド、2−第二ブトキシ−3−メトキシベンズアル
デヒド、2−第二ブトキシ−4−メトキシベンズ
アルデヒド、2−第二ブトキシ−5−メトキシベ
ンズアルデヒド、3−第二ブトキシ−4−メトキ
シベンズアルデヒド、4−第二ブトキシ−3−メ
トキシベンズアルデヒド、2,3,4−,2,
4,5−,2,4,6−又は3,4,5−トリメ
トキシベンズアルデヒドなどをあげることができ
る。
本発明の製造方法においてもう一方の原料とし
て用いられる一般式(4)のリン化合物は新規な化合
物であるが、常法によりトリアルキルホスフイ
ン、トリフエニルホスフイン、トリ置換フエニル
ホスフイン、トリアルキルホスフアイト、などの
リン化合物とα−ハロアシルアミノ安息香酸アル
キルエステルとの反応により容易に製造すること
ができる。この反応に用いられるホスフイン類及
びホスフアイト類はいずれも公知の化合物であ
り、市販品として入手しうるか、文献記載の方法
により製造することができる。このような化合物
として、トリエチルホスフイン、トリ−n−ブチ
ルホスフイン、トリ−n−オクチルホスフイン、
トリフエニルホスフイン、トリス(4−メトキシ
フエニル)ホスフイン、トリス(4−メチルフエ
ニル)ホスフイン、トリメチルホスフアイト、ト
リエチルホスフアイト、トリイソプロピルホスフ
アイト、トリ−n−ブチルホスフアイト、トリ−
n−デシルホスフアイトなどをあげることができ
る。
本発明の製造方法はいわゆるウイテイヒ反応の
一種であり、一般式(4)のリン化合物を塩基性物質
で処理して得られるリンイリド誘導体(5)と核置換
ベンズアルデヒド類(6)との反応によりオレフイン
結合を製造し、目的物を得るものである。この場
合、リンイリド誘導体(5)は通常反応系の中で製造
し、単離することなく次の反応に供せられるが、
安定なイリドの場合はいつたん単離、精製した
後、次の反応を行うこともできる。
一般式(4)のリン化合物からリンイリド誘導体(5)
への変換及び一般式(6)の核置換ベンズアルデヒド
類とのオレフイン生成反応は通常のウイテイヒ反
応及び類似反応の方法に従つて行うことができ
る。すなわち、一般式(4)のリン化合物を不活性有
機溶媒に溶解し、これに塩基性物質を加えて一定
時間反応させ、次いで一般式(6)の核置換ベンズア
ルデヒド類を加え、室温ないし冷却下に反応させ
る。この場合塩基性物質としては、ナトリウムア
ミド、水素化ナトリウム、ナトリウムメトキシ
ド、ナトリウムエトキシド、ポタシウム−t−ブ
トキシド、リチウムアミドなどのような化合物が
用いられる。又、溶媒としてはメタノール、エタ
ノール、クロロホルム、塩化メチレン、ジオキサ
ン、ジエチルエーテル、テトラヒドロフラン、ベ
ンゼン、トルエン、アセトニトリルなどを用いる
ことができる。
一般式(5)のリンイリド誘導体が安定なイリドの
場合、一般式(4)のリン化合物を水又はアルコール
に溶解又は懸濁し、水酸化ナトリウム、水酸化カ
リウム、炭酸ナトリウム、炭酸カリウムなどと反
応させてリンイリド誘導体(5)を製造し、単離精製
した後、これと核置換ベンズアルデヒド類(6)とを
不活性有機溶媒、例えばメタノール、エタノー
ル、クロロホルム、塩化メチレン、ジオキサン、
ジエチルエーテル、テトラヒドロフラン、ベンゼ
ン、トルエン、アセトニトリル、酢酸、酢酸エチ
ルなどに溶解し、室温ないし冷却下に反応させる
ことによつて目的物を製造することができる。
また、一般式(4)のリン化合物がトリアルキルホ
スフアイトから誘導される、〔(2−,3−又は4
−アルコキシルカルボニルフエニル)カルバモイ
ルメチル〕ホスホン酸ジアルキルエステルの場
合、不活性有機溶媒、例えばベンゼン、トルエ
ン、エタノール、ピリジンなどの溶媒中、ピペリ
ジンなどの有機塩基又はそれらの酢酸塩などの塩
を存在下に、核置換ベンズアルデヒド類(6)と反応
し、次いでアルコール中水酸化ナトリウムなどで
加水分解することによつても目的物を製造するこ
とができる。
本発明の製造方法を好適に実施するには、一般
式(4)で表わされるリン化合物を20〜40倍量のメタ
ノールに溶解し、これに必要量ないしやや過剰量
のナトリウムメトキシドを加え、室温ないし冷却
下で暫時かきまぜる。次いでこれに一般式(6)で表
わされる核置換ベンズアルデヒド類を加え、室温
ないし冷却下で2時間〜10数時間かきまぜる。溶
媒を減圧下に留去し、残留物を少量のアルコール
に溶解して氷水に注ぎ、塩酸酸性として析出する
結晶をろ取、水洗し、適当な溶媒で再結晶するこ
とにより一般式(1′)で表わされる化合物を得
る。さらに、得られた生成物を精製後又は粗結晶
のまま水又はアルコールに溶解又は懸濁し、必要
量ないしやや過剰量の水酸化ナトリウムを加え、
室温ないし加温下に十数分〜数時間かきまぜる。
溶媒を減圧下に濃縮した後塩酸酸性とし、析出す
る結晶をろ取、水洗し、適当な溶媒で再結晶する
ことにより一般式(1″)で表わされる化合物を得
る。
本発明方法において核置換基に水酸基をもつよ
うなベンズアルデヒド類(6)を用いる場合は、水酸
基をあらかじめアセチル基などによつて保護した
後、一般式(5)のイリド誘導体と反応させる方が好
ましい。この保護基は常法により除去することが
できる。
本製造方法によつて得られる一般式(1)の化合物
でR3が水素原子であるカルボン酸類(1″)は、
常法によりカルボキシル基を医薬品として許容さ
れる塩、例えばナトリウム、カリウム、カルシウ
ム、マグネシウムなどのような金属塩とすること
ができる。例えば、一般式(1″)の化合物のアル
コール溶液に、これと当モルの水酸化ナトリウム
の水溶液を加え、適当な時間加温することにより
容易にナトリウム塩とすることができる。あるい
は一般式(1′)の化合物のアルコール溶液に、こ
れと当モルの水酸化ナトリウム水溶液を加え、適
当な時間加温することにより、エステルの加水分
解と同時にナトリウム塩とすることもできる。
本発明の製造方法は従来の製造方法に比べ反応
操作が単純かつ容易であり、また反応条件が緩和
で副反応が起りにくく、精製も簡単である。更に
原料を含ま、全製造過程において有害ガス等の発
生は皆無であるという利点がある。
本発明によつて製造される芳香族カルボン酸ア
ミド誘導体は、気管支ぜん息、アトピー性皮フ
炎、アレルギー性鼻炎などアレルギーに起因する
種々の疾患の予防及び治療に広く使用することが
できる。
以下実施例及び参考例によつて本発明をさらに
詳細に説明する。なお各参考例及び実施例中にお
ける生成物の融点はいずれも未補正である。
参考例 1
トリフエニルホスフイン20.0gとN−クロルア
セチルアントラニル酸メチル12.0gとをベンゼン
130mlに溶解し、17時間還流した。冷後析出した
結晶をろ取し、ベンゼンで洗浄後乾燥して、〔(2
−メトキシカルボニルフエニル)カルバモイルメ
チル〕トリフエニルホスホニウムクロリド9.0g
を得た。
融点 163〜165℃(分解)
赤外線吸収スペクトル(KBr)
νCO:1705,1670cm-1
核磁気共鳴スペクトル(90MHz、CDCl3)
δ:3.70(3H,s),5.49(2H,d,J=15
Hz)、
7.0〜8.0(19H,m)、11.62(1H,s)
元素分析値(C28H25ClNO3として)
C% H% N%
計算値 68.64 5.14 2.86
実測値 68.42 5.11 2.68
参考例 2
対応する原料を用い、参考例1と実質的に同様
の操作を行なつて以下の化合物を得た。
Phosphorus ylide derivative represented by [Formula] (However, in each formula, X 1 and X 2 have the same meanings as above, and B + is a cation derived from a basic substance) and the general formula, (Y and n in the formula have the same meanings as above) By reacting with a nuclear-substituted benzaldehyde represented by the general formula, An aromatic carboxylic acid amide derivative represented by the formula (R 1 , R 2 , Y and n have the same meanings as above) is produced. Next, by hydrolyzing the ester group by a conventional method and further converting the product into a salt as desired, the product is converted into the general formula (R 1 and n in the formula have the same meanings as above,
Y′ may be the same or different, each being a linear or branched lower alkoxyl group or hydroxyl group having 1 to 4 carbon atoms) and drugs thereof. Physically acceptable salts can be produced. In the production method of the present invention, the reaction operation is extremely simple, and since the reaction proceeds under mild conditions such as at room temperature or under cooling, there are few by-products and purification is easy. Furthermore, there is no generation of harmful gases such as hydrogen halide gas generated during the production of acid halides. In this manner, the present manufacturing method can manufacture a target object much more easily and efficiently than conventional manufacturing methods. The nuclear-substituted benzaldehyde of general formula (6) used as a raw material in the production method of the present invention is a known compound and can be obtained as a commercial product or easily produced by methods described in literature. Examples of such compounds include 2,3-,2,4-,2,5- or 3,4-dihydroxybenzaldehyde, 2,3-,2,4
-,2,5- or 3,4-diacetoxybenzaldehyde, 2,3-,2,4-,2,5-,3,
4- or 3,5-dimethoxybenzaldehyde,
2,3-,2,4-,2,5- or 3,4-diethoxybenzaldihyde, 2,3-,2,4-,
2,5- or 3,4-dipropoxybenzaldehyde, 2,3-, 2,4-, 2,5- or 3,4
-dibutoxybenzaldehyde, 2-hydroxy-3-methoxybenzaldehyde, 2-hydroxy-4-methoxybenzaldehyde, 2-hydroxy-5-methoxybenzaldehyde, 3-hydroxy-4-methoxybenzaldehyde, 4-hydroxy-3-methoxybenzaldehyde, 2-
Acetoxy-3-methoxybenzaldehyde, 2
-acetoxy-4-methoxybenzaldehyde,
2-acetoxy-5-methoxybenzaldehyde, 3-acetoxy-4-methoxybenzaldehyde, 4-acetoxy-3-methoxybenzaldehyde, 2-ethoxy-3-methoxybenzaldehyde, 2-ethoxy-4-methoxybenzaldehyde, 2-ethoxy-5 -Methoxybenzaldehyde, 3-ethoxy-4-methoxybenzaldehyde, 4-ethoxy-3-methoxybenzaldehyde, 2-propoxy-3-methoxybenzaldehyde, 2-propoxy-4-methoxybenzaldehyde, 2-propoxy-5-methoxybenzaldehyde, 3 -Propoxy-4-methoxybenzaldehyde, 4-propoxy-3-methoxybenzaldehyde, 2-butoxy-3-methoxybenzaldehyde, 2-butoxy-4-methoxybenzaldehyde, 2-butoxy-5-methoxybenzaldehyde, 3-butoxy-4- Methoxybenzaldehyde, 4-butoxy-3-methoxybenzaldehyde, 2-isopropoxy-3-methoxybenzaldehyde, 2-isopropoxy-
4-methoxybenzaldehyde, 2-isopropoxy-5-methoxybenzaldehyde, 3-isopropoxy-4-methoxybenzaldehyde, 4
-isopropoxy-3-methoxybenzaldehyde, 2-sec-butoxy-3-methoxybenzaldehyde, 2-sec-butoxy-4-methoxybenzaldehyde, 2-sec-butoxy-5-methoxybenzaldehyde, 3-sec-butoxy-4- Methoxybenzaldehyde, 4-sec-butoxy-3-methoxybenzaldehyde, 2,3,4-,2,
Examples include 4,5-, 2,4,6- or 3,4,5-trimethoxybenzaldehyde. Although the phosphorus compound of general formula (4) used as the other raw material in the production method of the present invention is a new compound, trialkylphosphine, triphenylphosphine, trisubstituted phenylphosphine, trisubstituted phenylphosphine, trisubstituted It can be easily produced by reacting a phosphorus compound such as an alkyl phosphite with an α-haloacylaminobenzoic acid alkyl ester. The phosphines and phosphites used in this reaction are both known compounds and can be obtained as commercially available products or can be produced by methods described in literature. Such compounds include triethylphosphine, tri-n-butylphosphine, tri-n-octylphosphine,
Triphenylphosphine, tris(4-methoxyphenyl)phosphine, tris(4-methylphenyl)phosphine, trimethylphosphite, triethylphosphite, triisopropylphosphite, tri-n-butylphosphite, tri-
Examples include n-decyl phosphite. The production method of the present invention is a type of so-called Wittig reaction, in which a phosphorus ylide derivative (5) obtained by treating a phosphorus compound of general formula (4) with a basic substance is reacted with a nuclear-substituted benzaldehyde (6) to produce an olefin. It produces bonds and obtains the desired product. In this case, the phosphorus ylide derivative (5) is usually produced in the reaction system and subjected to the next reaction without isolation.
In the case of a stable ylide, the next reaction can be performed after isolation and purification. Phosphorus ylide derivative (5) from the phosphorus compound of general formula (4)
The conversion to olefin and the olefin-forming reaction with the nuclear-substituted benzaldehyde of general formula (6) can be carried out according to conventional Wittig reaction and similar reaction methods. That is, the phosphorus compound of general formula (4) is dissolved in an inert organic solvent, a basic substance is added thereto and reacted for a certain period of time, then the nuclear-substituted benzaldehyde of general formula (6) is added, and the mixture is heated at room temperature or under cooling. react to. In this case, compounds such as sodium amide, sodium hydride, sodium methoxide, sodium ethoxide, potassium t-butoxide, lithium amide, etc. are used as the basic substance. Further, as a solvent, methanol, ethanol, chloroform, methylene chloride, dioxane, diethyl ether, tetrahydrofuran, benzene, toluene, acetonitrile, etc. can be used. When the phosphorus ylide derivative of general formula (5) is a stable ylide, the phosphorus compound of general formula (4) is dissolved or suspended in water or alcohol and reacted with sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, etc. After the phosphorus ylide derivative (5) is produced and isolated and purified, it and the nuclear-substituted benzaldehyde (6) are mixed with an inert organic solvent such as methanol, ethanol, chloroform, methylene chloride, dioxane,
The desired product can be produced by dissolving it in diethyl ether, tetrahydrofuran, benzene, toluene, acetonitrile, acetic acid, ethyl acetate, etc. and reacting it at room temperature or under cooling. Further, the phosphorus compound of general formula (4) is derived from trialkyl phosphite [(2-, 3- or 4
-alkoxylcarbonylphenyl)carbamoylmethyl]phosphonic acid dialkyl esters, in an inert organic solvent such as benzene, toluene, ethanol, pyridine, etc., in the presence of an organic base such as piperidine or a salt thereof such as an acetate. Alternatively, the desired product can also be produced by reacting with a nuclear-substituted benzaldehyde (6) and then hydrolyzing with sodium hydroxide in alcohol. In order to suitably carry out the production method of the present invention, the phosphorus compound represented by the general formula (4) is dissolved in 20 to 40 times the amount of methanol, and a necessary amount or a slightly excessive amount of sodium methoxide is added thereto. Stir for a while at room temperature or under cooling. Next, a nuclear-substituted benzaldehyde represented by the general formula (6) is added to this, and the mixture is stirred at room temperature or under cooling for 2 to 10-odd hours. The solvent was distilled off under reduced pressure, the residue was dissolved in a small amount of alcohol and poured into ice water, and the crystals precipitated as acidified with hydrochloric acid were collected by filtration, washed with water, and recrystallized with an appropriate solvent to obtain the general formula (1' ) is obtained. Furthermore, the obtained product is dissolved or suspended in water or alcohol after purification or as a crude crystal, and a required amount or a slightly excessive amount of sodium hydroxide is added.
Stir at room temperature or under heating for about 10 minutes to several hours.
After concentrating the solvent under reduced pressure, it is acidified with hydrochloric acid, and the precipitated crystals are collected by filtration, washed with water, and recrystallized with an appropriate solvent to obtain the compound represented by the general formula (1''). In the method of the present invention, nuclear substitution When using benzaldehydes (6) having a hydroxyl group, it is preferable to protect the hydroxyl group with an acetyl group or the like before reacting with the ylide derivative of general formula (5). The carboxylic acids (1″) in which R 3 is a hydrogen atom in the compound of general formula (1) obtained by this production method are:
The carboxyl group can be converted into a pharmaceutically acceptable salt, such as a metal salt such as sodium, potassium, calcium, magnesium, etc., by conventional methods. For example, the sodium salt can be easily prepared by adding an equimolar amount of an aqueous solution of sodium hydroxide to an alcoholic solution of the compound of general formula (1'') and heating it for an appropriate period of time. Alternatively, the compound of general formula ( By adding an equimolar amount of sodium hydroxide aqueous solution to an alcoholic solution of the compound 1') and heating for an appropriate period of time, the ester can be hydrolyzed and simultaneously converted into a sodium salt.Production method of the present invention The reaction operation is simple and easy compared to conventional manufacturing methods, and the reaction conditions are mild, so side reactions are difficult to occur, and purification is easy.Furthermore, there is no generation of harmful gases during the entire manufacturing process, including raw materials. The aromatic carboxylic acid amide derivatives produced by the present invention can be widely used for the prevention and treatment of various diseases caused by allergies, such as bronchial asthma, atopic dermatitis, and allergic rhinitis. The present invention will be explained in more detail with reference to Examples and Reference Examples below.The melting points of the products in each Reference Example and Examples are uncorrected.Reference Example 1 Triphenylphosph 20.0 g of ester and 12.0 g of methyl N-chloroacetylanthranilate were mixed in benzene.
It was dissolved in 130 ml and refluxed for 17 hours. After cooling, the precipitated crystals were collected by filtration, washed with benzene and dried to obtain [(2
-Methoxycarbonylphenyl)carbamoylmethyl]triphenylphosphonium chloride 9.0g
I got it. Melting point 163-165℃ (decomposition) Infrared absorption spectrum (KBr) νCO: 1705, 1670cm -1 nuclear magnetic resonance spectrum (90MHz, CDCl 3 ) δ: 3.70 (3H, s), 5.49 (2H, d, J = 15
Hz), 7.0 to 8.0 (19H, m), 11.62 (1H, s) Elemental analysis value (as C 28 H 25 ClNO 3 ) C% H% N% Calculated value 68.64 5.14 2.86 Actual value 68.42 5.11 2.68 Reference example 2 Correspondence The following compound was obtained by performing substantially the same operation as in Reference Example 1 using the starting material.
【表】
参考例 3
トリエチルホスフアイト16.0gとN−クロルア
セチルアントラニル酸メチル9.0gとを140〜150
℃で3時間反応させた。反応終了後過剰のトリエ
チルホスフアイトを減圧下に留去して、油状物の
〔(2−メトキシカルボニルフエニル)カルバモイ
ルメチル〕ホスホン酸ジエチル13.0gを得た。
赤外線吸収スペクトル(液膜)
νCO:1685cm-1
核磁気共鳴スペクトル(90MHz、CDCl3)
δ:1.33(6H,t,J=7Hz)、3.03(2H,
d,J=20Hz)、3.89(3H,s)、4.13(2H,
q,J=7Hz)、4.22(2H,q,J=7
Hz)、6.9〜8.8(4H,m),11.22(1H,s)
参考例 4
対応する原料を用い、参考例3と実質的に同様
の操作を行なつて以下の化合物を得た。
[Table] Reference example 3 16.0 g of triethyl phosphite and 9.0 g of methyl N-chloroacetylanthranilate at 140 to 150
The reaction was carried out at ℃ for 3 hours. After the reaction was completed, excess triethyl phosphite was distilled off under reduced pressure to obtain 13.0 g of diethyl [(2-methoxycarbonylphenyl)carbamoylmethyl]phosphonate. Infrared absorption spectrum (liquid film) νCO: 1685cm -1 nuclear magnetic resonance spectrum (90MHz, CDCl 3 ) δ: 1.33 (6H, t, J = 7Hz), 3.03 (2H,
d, J=20Hz), 3.89 (3H, s), 4.13 (2H,
q, J = 7Hz), 4.22 (2H, q, J = 7
Hz), 6.9-8.8 (4H, m), 11.22 (1H, s) Reference Example 4 Using the corresponding raw materials, substantially the same operation as in Reference Example 3 was performed to obtain the following compound.
【表】
実施例 1
〔(2−メトキシカルボニルフエニル)カルバ
モイルメチル〕トリフエニルホスホニウムクロリ
ド5.16gに水150mlとベンゼン100mlを加え、氷冷
下かきまぜながら0.48gの水酸化ナトリウムを水
20mlに溶かした液を滴下した。滴下後さらに15分
間かきまぜた後ベンゼン層を分取し、水洗後無水
硫酸マグネシウムで乾燥した。溶媒を減圧下に留
去し、残留物をベンゼン−ジエチルエーテルで再
結晶して、〔(2−メトキシカルボニルフエニル)
カルバモイルメチレン〕トリフエニルホスホラン
4.7gを得た。
融点 160〜163℃
赤外線吸収スペクトル(KBr)
νCO:1670cm-1
核磁気共鳴スペクトル(90MHz、CDCl3)
δ:3.82(3H,s),6.6〜8.8(20H,m)、
10.43(1H,s)
元素分析値(C28H24NO3Pとして)
C% H% N%
計算値 74.16 5.33 3.09
実測値 74.19 5.14 3.86
〔(2−メトキシカルボニルフエニル)カルバ
モイルメチレン〕トリフエニルホスホラン500mg
と3,4−ジメトキシベンズアルデヒド183mgを
メタノール20mlに溶解し、室温で2.5時間かきま
ぜた。反応終了後溶媒を減圧下に留去し、残留物
をシリカゲルカラムクロマトグラフイー(溶出溶
媒:ベンゼン:酢酸エチル=5:1)により精製
し、ベンゼン−n−ヘキサンより再結晶してN−
(3,4−ジメトキシシンナモイル)アントラニ
ル酸メチル265mgを得た。
融点 141〜143℃
赤外線吸収スペクトル(KBr)
νCO:1700,1680cm-1
核磁気共鳴スペクトル(90MHz、CDCl3)
δ:3.83(3H,s),3.86(6H,s)、6.40
(1H,d,J=15Hz)、6.7〜8.9(8H,m)、
11.27(1H,s)
元素分析値C19H19NO5として
C% H% N%
計算値 66.85 5.61 4.10
実測値 67.00 5.58 3.85
実施例 2
〔(2−メトキシカルボニルフエニル)カルバ
モイルメチル〕トリフエニルホスホニウムクロリ
ド1.0gをメタノール40mlに加え、氷冷下かきま
ぜながらナトリウムメトキシド0.11gを加えた。
暫時かきまぜた後3,4−ジメトキシベンズアル
デヒド0.34gを加え、室温で17時間かきまぜた。
反応終了後溶媒を減圧下に留去し、残留物に塩酸
水溶液を加えて酸性とした後塩化メチレンで抽出
した。抽出液を水洗後無水硫酸マグネシウムで乾
燥し、溶媒を減圧下に留去した。残留物をシリカ
ゲルカラムクロマトグラフイー(溶出溶媒:ベン
ゼン:酢酸エチル=5:1)により精製し、ベン
ゼン−n−ヘキサンより再結晶してN−(3,4
−ジメトキシシンナモイル)アントラニル酸メチ
ル0.5gを得た。このものの物性は実施例1で得
た化合物と同一であることを示した。
実施例 3
〔(2−メトキシカルボニルフエニル)カルバ
モイルメチレン〕トリフエニルホスホラン453mg
とバニリン152mgとをメタノール20mlに加え、室
温で2時間かきまぜた。反応終了後溶媒を減圧下
に留去し、残留物をシリカゲルカラムクロマトグ
ラフイー(溶出溶媒:ベンゼン:酢酸エチル=
5:1)により精製した後、塩化メチレン−ジエ
チルエーテル−n−ヘキサンより再結晶してN−
(4−ヒドロキシ−3−メトキシシンナモイル)
アントラニル酸メチル263mgを得た。
融点 127〜128℃
赤外線吸収スペクトル(KBr)
νOH:3470cm-1
νCO:1670,1620cm-1
核磁気共鳴スペクトル(90MHz、d6−DMSO)
δ:3.82(3H,s),3.86(3H,s),6.6〜8.6
(9H,m)、9.42(1H,s)10.71(1H,s)
元素分析値(C18H17NO5として)
C% H% N%
計算値 66.04 5.24 4.28
実測値 66.16 5.03 4.12
N−(4−ヒドロキシ−3−メトキシシンナモ
イル)アントラニル酸メチル200mgをエタノール
5mlと水5mlの混液に加え、これに水酸化ナトリ
ウム100mgを加えて50℃で1時間かきまぜた。反
応終了後溶媒を減圧下に留去し、残留物に希塩酸
を加えて酸性とし、析出結晶をろ取した後アセト
ンより再結晶してN−(4−ヒドロキシ−3−メ
トキシシンナモイル)アントラニル酸150mgを得
た。
融点 231〜235℃
赤外線吸収スペクトル(KBr)
νOH:3500cm-1
νCO:1670,1650cm-1
核磁気共鳴スペクトル(90MHz、d6−DMSO)
δ:3.82(3H,s),6.5〜8.8(9H,m)、9.2
〜9.7(1H,br),11.22(1H,s)
元素分析値(C17H15NO5として)
C% H% N%
計算値 65.17 4.82 4.47
実測値 65.28 4.79 4.45
実施例 4
〔(3−メトキシカルボニルフエニル)カルバ
モイルメチル〕ホスホン酸ジエチル500mgをメタ
ノール20mlに溶解し、氷冷下かきまぜながら50%
水素化ナトリウム146mgを加え、さらに1時間か
きまぜた。これに3,4−ジメトキシベンズアル
デヒド252mgを加え、室温で6時間かきまぜた。
反応終了後溶媒を減圧下に留去し、残留物を少量
のエタノールに溶解して氷水に注ぎ希塩酸を加え
酸性とした。析出結晶をろ取、水洗し含水アルコ
ールで再結晶して3−(3,4−ジメトキシシン
ナモイルアミノ)安息香酸メチル360mgを得た。
融点 128〜130℃
赤外線吸収スペクトル(KBr)
νCO:1705,1650cm-1
核磁気共鳴スペクトル(90MHz、CDCl3)
δ:3.78(3H,s),3.85(6H,s),6.3〜8.3
(10H,m)
元素分析値(C19H19NO5として)
C% H% N%
計算値 66.85 5.61 4.10
実測値 67.09 5.79 3.89
実施例 5
〔(2−メトキシカルボニルフエニル)カルバ
モイルメチル〕ホスホン酸ジエチル500mgを乾燥
ジオキサン20mlに溶解し、氷冷下かきまぜながら
リチウムアミド70mgを徐々に加え、室温で1時間
かきまぜた。これに3,4−ジメトキシベンズア
ルデヒド252mgを加え、室温で18時間かきまぜた。
反応終了後反応液に希塩酸を加えて酸性とし、塩
化メチレンで抽出した。抽出液を水洗、乾燥し、
減圧下に溶媒を留去した。残留物をシリカゲルカ
ラムクロマトグラフイー(溶出溶媒:ベンゼン:
酢酸エチル=7:1)で精製した後ベンゼン−n
−ヘキサンより再結晶してN−(3,4−ジメト
キシシンナモイル)アントラニル酸メチル350mg
を得た。このものの物性は実施例1で得た化合物
と同一であることを示した。
実施例 6
〔(2−メトキシカルボニルフエニル)カルバ
モイルメチル〕ホスホン酸ジイソプロピル500mg
を乾燥アセトニトリル30mlに溶解し、氷冷下かき
まぜながらリチウムアミド64mgを加え、室温で1
時間かきまぜた。これに3,4−ジメトキシベン
ズアルデヒド232mgを加え、室温で17時間反応さ
せた。反応終了後実施例5と同様の操作を行い、
N−(3,4−ジメトキシシンナモイル)アント
ラニル酸メチル320mgを得た。このものの物性は
実施例1で得た化合物と同一であることを示し
た。
実施例 7
{1−〔(2−メトキシカルボニルフエニル)カ
ルバモイル〕エチル}ホスホン酸ジエチル500mg
をメタノール20mlに溶解し、氷冷下かきまぜなが
ら50%水素化ナトリウム140mgを加え、さらに室
温で1時間かきまぜた。これに3,4−ジメトキ
シベンズアルデヒド232mgを加え、室温で18時間
反応させた。反応終了後溶媒を減圧下に留去し、
残留物に希塩酸を加えて酸性とし、塩化メチレン
で抽出した。抽出液を水洗、乾燥し、減圧下に溶
媒を留去した。残留結晶を塩化メチレン−ジエチ
ルエーテル−n−ヘキサンで再結晶してN−(3,
4−ジメトキシ−α−メチルシンナモイル)アン
トラニル酸メチル344mgを得た。
融点 153〜155℃
赤外線吸収スペクトル(KBr)
νCO:1690,1665cm-1
核磁気共鳴スペクトル(90MHz、d6−DMSO)
δ:2.17(3H,s),3.77(6H,s),3.86
(3H,s),7.0〜8.7(9H,m),11.20(1H,
s)
元素分析値(C20H21NO5として)
C% H% N%
計算値 67.59 5.96 3.94
実測値 67.78 6.13 3.86
実施例 8
〔(2−メトキシカルボニルフエニル)カルバ
モイルメチル〕ホスホン酸ジエチル1.0gと3,
4−ジメトキシベンズアルデヒド570mgとをベン
ゼン30mlに溶解し、これにピペリジン100mgと酢
酸50mgを加え、脱水装置を付して50時間加熱還流
した。冷後溶媒を減圧下に留去し、残留物をエタ
ノール30mlに溶解し、水酸化カリウム1gを加え
て60℃で4時間加温した。反応終了後溶媒を減圧
下に留去し、残留物に氷水と希塩酸を加え析出す
る結晶をろ取、水洗し、乾燥後クロロホルムより
再結晶してN−(3,4−ジメトキシシンナモイ
ル)アントラニル酸634mgを得た。
融点 208〜208.5℃
赤外線吸収スペクトル(KBr)
νCO:1690,1655cm-1
核磁気共鳴スペクトル(90MHz、d6−DMSO)
δ:3.77(3H,s),3.79(3H,s),6.73
(1H,d,J=16Hz)、6.9〜8.7(8H,m)、
11.33(1H,s)
元素分析値(C18H17NO5として)
C% H% N%
計算値 66.04 5.24 4.28
実測値 66.12 5.22 4.26
実施例 9
N−(3,4−ジメトキシシンナモイル)アン
トラニル酸メチル1.7gに10%水酸化ナトリウム
水溶液40mlを加え1時間加温した。冷後析出した
結晶をろ取してN−(3,4−ジメトキシシンナ
モイル)アントラニル酸のナトリウム塩1.4gを
得た。
これを適量の水に加温、溶解し、希塩酸を加え
て酸性とした。析出した結晶をろ取、水洗し、乾
燥後クロロホルムより再結晶してN−(3,4−
ジメトキシシンナモイル)アントラニル酸1.0g
を得た。このものの物性は実施例8で得たものと
同一であることを示した。
実施例 10
対応する原料を用い、前記各実施例と実質的に
同様の操作を行うことにより、以下の化合物を得
ることができた。
[Table] Example 1 Add 150 ml of water and 100 ml of benzene to 5.16 g of [(2-methoxycarbonylphenyl)carbamoylmethyl]triphenylphosphonium chloride, and add 0.48 g of sodium hydroxide to the water while stirring under ice cooling.
A solution dissolved in 20 ml was added dropwise. After the addition, the mixture was stirred for another 15 minutes, and the benzene layer was separated, washed with water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was recrystallized from benzene-diethyl ether to give [(2-methoxycarbonylphenyl)
Carbamoylmethylene]triphenylphosphorane
4.7g was obtained. Melting point 160-163℃ Infrared absorption spectrum (KBr) νCO: 1670cm -1 nuclear magnetic resonance spectrum (90MHz, CDCl 3 ) δ: 3.82 (3H, s), 6.6-8.8 (20H, m),
10.43 (1H, s) Elemental analysis value (as C 28 H 24 NO 3 P) C% H% N% Calculated value 74.16 5.33 3.09 Actual value 74.19 5.14 3.86 [(2-methoxycarbonylphenyl)carbamoylmethylene] triphenylphospho Ran 500mg
and 183 mg of 3,4-dimethoxybenzaldehyde were dissolved in 20 ml of methanol and stirred at room temperature for 2.5 hours. After the reaction, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: benzene: ethyl acetate = 5:1) and recrystallized from benzene-n-hexane to obtain N-
265 mg of methyl (3,4-dimethoxycinnamoyl)anthranilate was obtained. Melting point 141-143℃ Infrared absorption spectrum (KBr) νCO: 1700, 1680cm -1 nuclear magnetic resonance spectrum (90MHz, CDCl 3 ) δ: 3.83 (3H, s), 3.86 (6H, s), 6.40
(1H, d, J=15Hz), 6.7-8.9 (8H, m),
11.27 (1H, s) Elemental analysis value C 19 H 19 NO 5 C% H% N% Calculated value 66.85 5.61 4.10 Actual value 67.00 5.58 3.85 Example 2 [(2-methoxycarbonylphenyl)carbamoylmethyl]triphenylphosphonium 1.0 g of chloride was added to 40 ml of methanol, and 0.11 g of sodium methoxide was added while stirring under ice cooling.
After stirring for a while, 0.34 g of 3,4-dimethoxybenzaldehyde was added, and the mixture was stirred at room temperature for 17 hours.
After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was made acidic by adding aqueous hydrochloric acid solution, and then extracted with methylene chloride. The extract was washed with water, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (eluent: benzene:ethyl acetate = 5:1) and recrystallized from benzene-n-hexane to obtain N-(3,4
-dimethoxycinnamoyl) methyl anthranilate 0.5 g was obtained. The physical properties of this product were shown to be the same as the compound obtained in Example 1. Example 3 [(2-methoxycarbonylphenyl)carbamoylmethylene]triphenylphosphorane 453mg
and 152 mg of vanillin were added to 20 ml of methanol and stirred at room temperature for 2 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was subjected to silica gel column chromatography (elution solvent: benzene: ethyl acetate =
5:1) and then recrystallized from methylene chloride-diethyl ether-n-hexane to obtain N-
(4-hydroxy-3-methoxycinnamoyl)
263 mg of methyl anthranilate was obtained. Melting point 127-128℃ Infrared absorption spectrum (KBr) νOH: 3470cm -1 νCO: 1670, 1620cm -1 Nuclear magnetic resonance spectrum (90MHz, d 6 -DMSO) δ: 3.82 (3H, s), 3.86 (3H, s) ,6.6~8.6
(9H, m), 9.42 (1H, s) 10.71 (1H, s) Elemental analysis value (as C 18 H 17 NO 5 ) C% H% N% Calculated value 66.04 5.24 4.28 Actual value 66.16 5.03 4.12 N-(4 -Hydroxy-3-methoxycinnamoyl) 200 mg of methyl anthranilate was added to a mixture of 5 ml of ethanol and 5 ml of water, 100 mg of sodium hydroxide was added thereto, and the mixture was stirred at 50°C for 1 hour. After the reaction, the solvent was distilled off under reduced pressure, the residue was made acidic by adding dilute hydrochloric acid, the precipitated crystals were collected by filtration, and then recrystallized from acetone to obtain N-(4-hydroxy-3-methoxycinnamoyl)anthranilic acid. Obtained 150mg. Melting point 231-235℃ Infrared absorption spectrum (KBr) νOH: 3500cm -1 νCO: 1670, 1650cm -1 Nuclear magnetic resonance spectrum (90MHz, d6 -DMSO) δ: 3.82 (3H, s), 6.5-8.8 (9H, m), 9.2
~9.7 (1H, br), 11.22 (1H, s) Elemental analysis value (as C 17 H 15 NO 5 ) C% H% N% Calculated value 65.17 4.82 4.47 Actual value 65.28 4.79 4.45 Example 4 [(3-methoxy Dissolve 500 mg of diethyl (carbonylphenyl)carbamoylmethyl phosphonate in 20 ml of methanol and stir under ice cooling until 50%
146 mg of sodium hydride was added and stirred for an additional hour. To this was added 252 mg of 3,4-dimethoxybenzaldehyde, and the mixture was stirred at room temperature for 6 hours.
After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was dissolved in a small amount of ethanol, poured into ice water, and made acidic by adding dilute hydrochloric acid. The precipitated crystals were collected by filtration, washed with water, and recrystallized with aqueous alcohol to obtain 360 mg of methyl 3-(3,4-dimethoxycinnamoylamino)benzoate. Melting point 128-130℃ Infrared absorption spectrum (KBr) νCO: 1705, 1650cm -1 Nuclear magnetic resonance spectrum (90MHz, CDCl 3 ) δ: 3.78 (3H, s), 3.85 (6H, s), 6.3-8.3
(10H, m) Elemental analysis value (as C 19 H 19 NO 5 ) C% H% N% Calculated value 66.85 5.61 4.10 Actual value 67.09 5.79 3.89 Example 5 [(2-methoxycarbonylphenyl)carbamoylmethyl]phosphonic acid 500 mg of diethyl was dissolved in 20 ml of dry dioxane, and while stirring under ice cooling, 70 mg of lithium amide was gradually added, followed by stirring at room temperature for 1 hour. To this was added 252 mg of 3,4-dimethoxybenzaldehyde, and the mixture was stirred at room temperature for 18 hours.
After the reaction was completed, dilute hydrochloric acid was added to the reaction solution to make it acidic, and the mixture was extracted with methylene chloride. Wash the extract with water, dry it,
The solvent was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography (elution solvent: benzene:
After purification with ethyl acetate = 7:1), benzene-n
-Methyl N-(3,4-dimethoxycinnamoyl)anthranilate 350 mg after recrystallization from hexane
I got it. The physical properties of this product were shown to be the same as the compound obtained in Example 1. Example 6 [(2-methoxycarbonylphenyl)carbamoylmethyl]diisopropylphosphonate 500mg
Dissolve in 30 ml of dry acetonitrile, add 64 mg of lithium amide while stirring under ice cooling, and dissolve at room temperature for 1 hour.
I stirred the time. 232 mg of 3,4-dimethoxybenzaldehyde was added to this, and the mixture was reacted at room temperature for 17 hours. After the reaction was completed, the same operation as in Example 5 was carried out,
320 mg of methyl N-(3,4-dimethoxycinnamoyl)anthranilate was obtained. The physical properties of this product were shown to be the same as the compound obtained in Example 1. Example 7 {1-[(2-methoxycarbonylphenyl)carbamoyl]ethyl}diethylphosphonate 500 mg
was dissolved in 20 ml of methanol, 140 mg of 50% sodium hydride was added while stirring under ice cooling, and the mixture was further stirred at room temperature for 1 hour. 232 mg of 3,4-dimethoxybenzaldehyde was added to this, and the mixture was reacted at room temperature for 18 hours. After the reaction is complete, the solvent is distilled off under reduced pressure.
The residue was acidified with dilute hydrochloric acid and extracted with methylene chloride. The extract was washed with water, dried, and the solvent was distilled off under reduced pressure. The remaining crystals were recrystallized from methylene chloride-diethyl ether-n-hexane to give N-(3,
344 mg of methyl 4-dimethoxy-α-methylcinnamoyl)anthranilate was obtained. Melting point 153-155℃ Infrared absorption spectrum (KBr) νCO: 1690, 1665cm -1 nuclear magnetic resonance spectrum (90MHz, d 6 -DMSO) δ: 2.17 (3H, s), 3.77 (6H, s), 3.86
(3H, s), 7.0~8.7 (9H, m), 11.20 (1H,
s) Elemental analysis value (as C 20 H 21 NO 5 ) C% H% N% Calculated value 67.59 5.96 3.94 Actual value 67.78 6.13 3.86 Example 8 [(2-methoxycarbonylphenyl)carbamoylmethyl]diethyl phosphonate 1.0 g and 3,
570 mg of 4-dimethoxybenzaldehyde was dissolved in 30 ml of benzene, 100 mg of piperidine and 50 mg of acetic acid were added thereto, a dehydrator was attached, and the mixture was heated under reflux for 50 hours. After cooling, the solvent was distilled off under reduced pressure, the residue was dissolved in 30 ml of ethanol, 1 g of potassium hydroxide was added, and the mixture was heated at 60° C. for 4 hours. After the reaction, the solvent was distilled off under reduced pressure, ice water and dilute hydrochloric acid were added to the residue, and the precipitated crystals were collected by filtration, washed with water, dried, and recrystallized from chloroform to give N-(3,4-dimethoxycinnamoyl)anthranyl. 634 mg of acid was obtained. Melting point 208-208.5℃ Infrared absorption spectrum (KBr) νCO: 1690, 1655cm -1 nuclear magnetic resonance spectrum (90MHz, d 6 -DMSO) δ: 3.77 (3H, s), 3.79 (3H, s), 6.73
(1H, d, J=16Hz), 6.9~8.7 (8H, m),
11.33 (1H, s) Elemental analysis value (as C 18 H 17 NO 5 ) C% H% N% Calculated value 66.04 5.24 4.28 Actual value 66.12 5.22 4.26 Example 9 N-(3,4-dimethoxycinnamoyl)anthranilic acid 40 ml of 10% aqueous sodium hydroxide solution was added to 1.7 g of methyl and heated for 1 hour. After cooling, the precipitated crystals were collected by filtration to obtain 1.4 g of sodium salt of N-(3,4-dimethoxycinnamoyl)anthranilic acid. This was heated and dissolved in an appropriate amount of water, and diluted hydrochloric acid was added to make it acidic. The precipitated crystals were collected by filtration, washed with water, dried, and recrystallized from chloroform to give N-(3,4-
Dimethoxycinnamoyl) anthranilic acid 1.0g
I got it. The physical properties of this product were shown to be the same as those obtained in Example 8. Example 10 The following compounds could be obtained by performing substantially the same operations as in each of the above Examples using the corresponding raw materials.
【表】【table】
Claims (1)
低級アルキル基であり、R2は炭素数が1〜3の
低級アルキル基であり、Zは式【式】 又は【式】 (ただし、各式中のX1は炭素数が1〜10のア
ルキル基、フエニル基又は置換フエニル基、X2
は炭素数が1〜10のアルコキシル基、Halは塩素
原子、臭素原子又はヨウ素原子)で示される基で
ある〕 で表わされるリン化合物を塩基性物質で処理し
て、一般式 〔式中のR1及びR2は前記と同じ意味をもち、
Z′は式 (X1)3P−又は【式】 (ただし、各式中のX1およびX2は前記と同じ
意味をもち、B+は塩基性物質から誘導される陽
イオンである)で示される基である〕 で表わされるリンイリド誘導体を製造し、次いで
これと、一般式 (式中のYは互いに同じでも異なつていてもよ
く、それぞれ炭素数が1〜4の直鎖状又は枝分れ
状の低級アルコキシル基、水酸基及び炭素数が2
〜5の低級アシルオキシ基の中から選ばれる基で
あり、nは2又は3である) で表わされる核置換ベンズアルデヒド類とを反応
させることを特徴とする、一般式 (式中のR1,R2,Y及びnは前記と同じ意味
をもつ)で表わされる芳香族カルボン酸アミド誘
導体の製造方法。 2 一般式 〔式中のR1は水素原子又は炭素数が1〜3の
低級アルキル基であり、R2は炭素数が1〜3の
低級アルキル基であり、Zは式【式】 又は【式】 (ただし、各式中のX1は炭素数が1〜10のア
ルキル基、フエニル基又は置換フエニル基、X2
は炭素数が1〜10のアルコキシル基、Halは塩素
原子、臭素原子又はヨウ素原子である)で示され
る基である〕 で表わされるリン化合物を塩基性物質で処理し
て、一般式 (式中のR1及びR2は前記と同じ意味をもち、
Z′は式 (X1)3P−又は【式】 (ただし、各式中のX1及びX2は前記と同じ意
味をもち、B+は塩基性物質から誘導される陽イ
オンである)で示される基である〕 で表わされるリンイリド誘導体を製造し、これ
と、一般式 (式中のYは互いに同じでも異なつていてもよ
く、それぞれ炭素数が1〜4の直鎖状又は枝分れ
状の低級アルコキシル基、水酸基及び炭素数が2
〜5の低級アシルオキシ基の中から選ばれる基で
あり、nは2又は3である) で表わされる核置換ベンズアルデヒド類とを反応
させ、次いで常法によりエステル基を加水分解
し、さらに所望によりその生成物を塩に変えるこ
とを特徴とする、一般式 (式中のR1及びnは前記と同じ意味をもち、
Y′は互いに同じでも異なつていてもよく、それ
ぞれ炭素数が1〜4の直鎖状又は枝分れ状の低級
アルコキシル基又は水酸基である) で表わされる芳香族カルボン酸アミド誘導体及び
薬理学的に許容される塩の製造方法。[Claims] 1. General formula [In the formula, R 1 is a hydrogen atom or a lower alkyl group having 1 to 3 carbon atoms, R 2 is a lower alkyl group having 1 to 3 carbon atoms, and Z is the formula [formula] or [formula] ( However, X 1 in each formula is an alkyl group having 1 to 10 carbon atoms, a phenyl group, or a substituted phenyl group, X 2
is an alkoxyl group having 1 to 10 carbon atoms, and Hal is a group represented by a chlorine atom, bromine atom, or iodine atom.] A phosphorus compound represented by the following is treated with a basic substance to form the general formula [R 1 and R 2 in the formula have the same meanings as above,
Z′ is the formula (X 1 ) 3 P− or [Formula] (However, X 1 and X 2 in each formula have the same meanings as above, and B + is a cation derived from a basic substance) A phosphorus ylide derivative represented by (Y in the formula may be the same or different, and each has a linear or branched lower alkoxyl group having 1 to 4 carbon atoms, a hydroxyl group, and a hydroxyl group having 2 carbon atoms.
-5 lower acyloxy groups, n is 2 or 3) A method for producing an aromatic carboxylic acid amide derivative represented by the formula (R 1 , R 2 , Y and n have the same meanings as above). 2 General formula [In the formula, R 1 is a hydrogen atom or a lower alkyl group having 1 to 3 carbon atoms, R 2 is a lower alkyl group having 1 to 3 carbon atoms, and Z is the formula [formula] or [formula] ( However, X 1 in each formula is an alkyl group having 1 to 10 carbon atoms, a phenyl group, or a substituted phenyl group, X 2
is an alkoxyl group having 1 to 10 carbon atoms, and Hal is a chlorine atom, bromine atom, or iodine atom.] The phosphorus compound represented by is treated with a basic substance to form the general formula (R 1 and R 2 in the formula have the same meanings as above,
Z' is the formula (X 1 ) 3 P- or [Formula] (However, X 1 and X 2 in each formula have the same meanings as above, and B + is a cation derived from a basic substance) A phosphorus ylide derivative represented by the following is prepared, and this and the general formula (Y in the formula may be the same or different, and each has a linear or branched lower alkoxyl group having 1 to 4 carbon atoms, a hydroxyl group, and a hydroxyl group having 2 carbon atoms.
~5 lower acyloxy groups, n is 2 or 3)), then the ester group is hydrolyzed by a conventional method, and if desired, the ester group is General formula, characterized by converting the product into a salt (R 1 and n in the formula have the same meanings as above,
Y' may be the same or different, and each is a linear or branched lower alkoxyl group or hydroxyl group having 1 to 4 carbon atoms) and pharmacology of aromatic carboxylic acid amide derivatives represented by A method for producing salt that is acceptable to the public.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12820783A JPS6019754A (en) | 1983-07-14 | 1983-07-14 | Production of aromatic carboxylic acid amide derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12820783A JPS6019754A (en) | 1983-07-14 | 1983-07-14 | Production of aromatic carboxylic acid amide derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6019754A JPS6019754A (en) | 1985-01-31 |
| JPH0337539B2 true JPH0337539B2 (en) | 1991-06-05 |
Family
ID=14979125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12820783A Granted JPS6019754A (en) | 1983-07-14 | 1983-07-14 | Production of aromatic carboxylic acid amide derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6019754A (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2244704B (en) * | 1990-05-04 | 1995-05-17 | Consultants Suppliers Limited | Substituted benzene compounds |
| US6127392A (en) * | 1997-08-05 | 2000-10-03 | American Home Products Corporation | Anthranilic acid analogs |
| MX352516B (en) | 2006-07-05 | 2017-04-06 | Fibrotech Therapeutics Pty Ltd | Therapeutic compounds. |
| CA2709937C (en) | 2007-12-21 | 2016-03-22 | Fibrotech Therapeutics Pty Ltd | Halogenated analogues of anti-fibrotic agents |
| CN102574843B (en) | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | Fused ring analogs of antifibrotic agents |
| JP2012184169A (en) * | 2011-03-03 | 2012-09-27 | Dainippon Printing Co Ltd | Method for producing base-generating agent |
| JP7185631B2 (en) | 2017-02-03 | 2022-12-07 | サータ セラピューティクス プロプライエタリー リミテッド | antifibrotic compound |
| CN110357789B (en) * | 2018-04-11 | 2022-09-30 | 华东理工大学 | N-substituted acrylamide derivative as DHODH inhibitor and preparation and application thereof |
| KR20250141837A (en) | 2020-03-06 | 2025-09-29 | 시므라이즈 아게 | Cosmetic or pharmaceutical use of avenanthramide L |
| EP4114348A1 (en) | 2020-03-06 | 2023-01-11 | Symrise AG | Composition comprising an aventhramide or an analogue thereof with improved stability |
| ES3001283T3 (en) | 2020-03-06 | 2025-03-05 | Symrise Ag | Avenanthramide compositions with improved solubility comprising 4-hydroxyphenone |
| BR112022017293A2 (en) | 2020-03-06 | 2022-10-11 | Symrise Ag | OATS COMPOSITION OR EXTRACT INCLUDING AVENANTRAMIDE AND SS-GLUCAN |
| WO2021175452A1 (en) | 2020-03-06 | 2021-09-10 | Symrise Ag | Composition comprising an avenanthramide or an analogue thereof with improved skin penetration |
-
1983
- 1983-07-14 JP JP12820783A patent/JPS6019754A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6019754A (en) | 1985-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5128331A (en) | Method for lowering plasma lipid levels or blood pressure | |
| JPH0337539B2 (en) | ||
| JPS58174393A (en) | Diphosphoric acid derivative, manufacture and antiphlogistic and antiarrhythmic pharmaceutical medicine | |
| US4073936A (en) | Hypolipidemic allene carboxylic esters | |
| US3658858A (en) | Di-(6-methoxy-2-naphthyl) cadmium | |
| US3468939A (en) | 4- and 5-aryl-1-naphthaleneacetic acid compounds | |
| JPH032134B2 (en) | ||
| JPH05500208A (en) | Treatment for diseases caused by abnormal calcium metabolism | |
| KR900001006B1 (en) | Process for the optical resolution of racemic mixtures of alpha-naphthyl propionic acid | |
| JPH05246967A (en) | Diastereoisomers of alpha-naphthyl-propionic amide | |
| JPH0358337B2 (en) | ||
| JPS58174394A (en) | Diphosphonic acid derivative, manufacture and anti-arrhythmic pharmaceutical medicine | |
| IE48791B1 (en) | Anti-arthritic hydroxyacetic acid derivatives,pharmaceutical compositions thereof,and processes for their manufacture | |
| JPH0373557B2 (en) | ||
| JP3340732B1 (en) | Method for producing cyclopentabenzofuran derivative and novel compound as raw material for production | |
| JP3541421B2 (en) | Allene-containing α-substituted cyclopentenone derivatives and method for producing the same | |
| EP0142979B1 (en) | Improvements in the production of halocyclopropyl-substituted phenoxyalkanoic acids and esters | |
| US4965401A (en) | Process for the preparation of 2-propyl-2-pentenoic acid and its esters | |
| JP3228486B2 (en) | Hydroxyketone derivative and method for producing the same | |
| WO2014040476A1 (en) | Process for synthesising brominated eneyne compound e, e-22-bromo-9,11,19-triyne-17,21-diene docosanoic acid ester | |
| JPH0533216B2 (en) | ||
| JPS6042343A (en) | Production of dihydropolyprenyl alcohol | |
| JPH0321013B2 (en) | ||
| JPH10168049A (en) | Method for producing amide derivative | |
| JP2001031623A (en) | Production of 2-substituted propionic acid |